Company profile: Carmot Therapeutics
1.1 - Company Overview
Company description
- Provider of drug discovery and development for inflammatory, metabolic, and neurological diseases, leveraging its patented Chemotype Evolution platform to accelerate discovery of disease‑modifying therapies. Pipeline includes CT‑388 and CT‑868 (dual GLP‑1/GIP agonists), CT‑996 (oral GLP‑1 agonist) for obesity and type 1 diabetes, and CT‑PYY for Prader‑Willi syndrome.
Products and services
- Chemotype Evolution: A patented discovery platform that identifies and optimizes drug candidates via library synthesis and screening, accelerating discovery of disease-modifying therapies by targeting fundamental disease causes
- CT-388: A Phase-2 ready, dual GLP-1/GIP receptor agonist engineered for obesity treatment, administered once weekly via subcutaneous injection, combining GLP-1 and GIP pathway activation in a single therapeutic
- CT-868: A Phase-2, once-daily subcutaneous injectable dual GLP-1/GIP receptor agonist developed to treat type 1 diabetes in patients with overweight or obesity, enabling combined incretin receptor engagement per dose
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Carmot Therapeutics
Akarna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akarna Therapeutics company profile →
MRM Health
HQ: Belgium
Website
- Description: Provider of microbiome-based therapeutics and development platforms, including the CORAL platform to design optimized microbial consortia, SHIME simulator of the human gut, and Optimized Consortia therapeutics. Offers clinical programs in inflammatory bowel diseases (Ulcerative Colitis, Pouchitis) with MH002, and preclinical programs in CNS, metabolic (Type 2 Diabetes, NAFLD/NASH) and auto-immune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MRM Health company profile →
Neurocrine Biosciences
HQ: United States
Website
- Description: Provider of therapies for neurological and endocrine-related diseases, including FDA-approved Ingrezza (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa and Oriahnn (commercialized by AbbVie) for endometriosis pain and heavy menstrual bleeding associated with uterine fibroids; and investigational Crinecerfont for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, NBI-1065890 (VMAT2 inhibitor), and NBI-1065845 (AMPA potentiator).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurocrine Biosciences company profile →
Genfit
HQ: France
Website
- Description: Provider of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, dedicated to discovery and development in areas with considerable unmet medical needs where approved treatments are lacking; a late-stage biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genfit company profile →
Clarus Therapeutics
HQ: United States
Website
- Description: Provider of androgen-based biopharmaceutical therapies, developing medicines for men and women, including JATENZO, an oral testosterone replacement therapy for men with conditions associated with a deficiency or absence of endogenous testosterone.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Carmot Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Carmot Therapeutics
2.2 - Growth funds investing in similar companies to Carmot Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Carmot Therapeutics
4.2 - Public trading comparable groups for Carmot Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →